<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02729623</url>
  </required_header>
  <id_info>
    <org_study_id>cannaHALER-1A</org_study_id>
    <nct_id>NCT02729623</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics, Safety, and Ease of Use of a Portable Metered-Dose Cannabis Inhaler</brief_title>
  <official_title>The Pharmacokinetics, Safety, and Ease of Use of a Portable Metered-Dose Cannabis Inhaler: A Phase 1a Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite Systems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kite Systems</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Growing evidence supports the use of inhaled cannabis for neuropathic pain; the lack of
      standard inhaled dosing holds a major obstacle in cannabis becoming a pharmacological
      treatment for neuropathic pain. The objective of this study is to explore the
      pharmacokinetics, safety, tolerability, and ease of use of a portable metered-dose inhaler,
      (i.e. CannaHALER) for cannabis in a cohort of 12 healthy volunteers. In a single escalating
      dose methodology, open-label study, patients will inhale a single 10 ± 0.1 mg / 15 ± 0.1 mg /
      20 ± 0.1 mg / 25 ± 0.1 mg dose of cannabis using the Kite Systems cannaHALER cannabis Inhaler
      device. Blood samples will be taken at baseline and up to 30 minutes. Adverse events will be
      monitored following the inhalation.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Δ9-tetrahydrocannabinol levels (THC)</measure>
    <time_frame>30 Minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event monitoring</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Δ9 Carboxy-THC levels</measure>
    <time_frame>30 Minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short Blessed cognitive Test</measure>
    <time_frame>30 Minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>120 Minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate</measure>
    <time_frame>120 Minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>120 Minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single CannaHALER dose 10 ± 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 10 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single CannaHALER dose 15 ± 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 15 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single CannaHALER dose 20 ± 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 20 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single CannaHALER dose 25 ± 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 25 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kite Systems cannaHALER cannabis Inhaler.</intervention_name>
    <arm_group_label>Single CannaHALER dose 10 ± 0.1 mg</arm_group_label>
    <arm_group_label>Single CannaHALER dose 15 ± 0.1 mg</arm_group_label>
    <arm_group_label>Single CannaHALER dose 20 ± 0.1 mg</arm_group_label>
    <arm_group_label>Single CannaHALER dose 25 ± 0.1 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 30-70 years;

          -  healthy

          -  if applicable, negative pregnancy test (β human chorionic gonadotropin pregnancy
             test).

        Exclusion Criteria:

          -  significant cardiac or pulmonary disease,

          -  history of a psychotic or anxiety disorder,

          -  pregnancy, pregnancy attempt or breastfeeding,

          -  presence of a neuropathic or non-neuropathic pain,

          -  low blood pressure, below 90 mm Hg (systolic)

          -  Diabetes is diagnosed,

          -  first degree family history of psychotic or anxiety disorder,

          -  history of drug addiction,

          -  history of drug misuse,

          -  using the following drugs: Rifampicin, Rifabutin, Carbamazepine, Phenobarbital,
             Primidone,

          -  using the following plants: Hypericum perforatum, troglitazone,

          -  Alcohol consumption up to 12 hours before the study,

          -  abnormal parameters such as Heart Rate above 100 BPM, Blood pressure, below 90 mm Hg
             (systolic), Saturation below 91 percent,

          -  Cannabis use up to 12 hours before the study,

          -  health condition which could affect or alter the experiment results,

          -  Volunteer has a legal guardian.

          -  Chronic use of drugs,

          -  age less than 30 or more than 70,

          -  a health condition that could affect the outcome of the trial or constitutes a risk
             factor for participation in the trial.

          -  The experiment will not include special populations such as pregnant women, children
             and without judgement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ofir Ben-Ishay, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2016</study_first_posted>
  <last_update_submitted>July 22, 2016</last_update_submitted>
  <last_update_submitted_qc>July 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

